Cresilon, Walter Reed Forge Research Partnership on TBI Treatments

Cresilon Inc. (“Cresilon”) and Walter Reed Army Institute of Research (WRAIR) are joining forces on traumatic brain injury treatment options.

The two entities have forged a Cooperative Research and Development Agreement (CRADA) to advance the development of medical technologies used to treat traumatic brain injuries, particularly those sustained by soldiers on the battlefield. WRAIR is the largest biomedical research facility administered by the U.S. Department of Defense.
 
Utilizing Cresilon’s proprietary hemostatic gel technology that stops bleeding in seconds without manual pressure, this joint effort will aim to address a critical gap in military medical treatment. While traumatic brain injury (TBI) is a significant danger to soldiers with major long-term or fatal results, there are currently no U.S. Food and Drug Administration-approved treatment options to address penetrating ballistic-like brain injury (PBBI). The CRADA aims to address this capability gap by employing Cresilon’s technology as a novel, ground-breaking solution that potentially provides both hemostatic and neuroprotective support following PBBI. The data resulting from the CRADA’s evaluation of Cresilon’s gel technology in a severe PBBI research model will be shared between Cresilon and WRAIR and could form the foundation of future commercial opportunities.
 
“Cresilon is extremely proud and honored to be supporting the DoD and WRAIR in this critically important work,” Cresilon CEO Joe Landolina said. “This collaboration is a testament to the potential of our technology, and we are truly hopeful that it can make a difference in the treatment of TBI and in the precious lives of our soldiers.”
 
Cresilon is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices utilizing the company’s proprietary hydrogel technology. The company’s plant-based technology has revolutionized the current standard by stopping traumatic bleeds in seconds without the need for manual pressure. 
 
Around the world, WRAIR works alongside civilian researchers, medical professionals, and military personnel to develop and test products that will ultimately reduce the impact of some of the most dangerous and debilitating diseases. WRAIR provides unique research capabilities and innovative medical solutions to a range of Force Health Protection and Readiness challenges currently facing U.S. Service Members, along with threats anticipated during future operations.